Adaptive Biotechnologies Corporation (ADPT) Leapt 18% In Extended Trading. Here’s Why?


Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, has seen its share price surging 18.16% in extended trading to $49.90. The rise, which came offsetting the decline of -3.32% the company has faced in the regular session, was all because of approval granted to its Covid-related test.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What actually drove the surge?

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Harnessing the intrinsic biology of the immune system is the main point of focus of Adaptive Biotechnologies to transform the way disease is diagnosed and treated. In ADPT’s view, the adaptive immune system is the most finely tuned natural way of detecting and treating most diseases, but as a result of being unable to properly decode its pattern, the system has been unavailable to medical professionals as a diagnostic and therapeutic tool. ADPT has developed three commercial products, and also various types of diseases such as cancer, infectious diseases, and autoimmune conditions, are being targeted by the company through its several product candidates.

Read More

In a press release made on Friday, Adaptive announces that the FDA has approved an Emergency Use Authorization (EUA) of the company’s T-Detect COVID to confirm current as well as previous variants of COVID infection.

  • This first-of-its-kind test in a TCR-Antigen Map collaboration with Microsoft (Nasdaq: MSFT) is the first indication from this collaboration.
  • Approval of that EUA was based on a clinical validation study showing that T-Detect COVID displayed high sensitivity (97.1%) when used with RT-PCR from the date of diagnosis.
  • Sensitivity is the degree to which a test can identify a true positive case correctly.
  • T-Detect COVID also demonstrated 100% specificity which is the degree to which a test can identify a true negative case correctly.

    Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

  • When there are no adequate, approved, and available alternatives to medical products in an emergency, the FDA can grant a EUA for use to diagnose, treat, or prevent serious diseases or conditions.


Please enter your comment!
Please enter your name here